Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
IntroductionThe optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined.MethodsTo compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthra…